Cramer's Investing Club: Buy Eli Lilly's drop on drug delay news because it won't matter long term

We see the pushback of donanemab's accelerated approval submission as just a speed bump.

from Health and Science https://ift.tt/eu17rsPRv
https://ift.tt/QkKTRz4UJ
https://ift.tt/W0HUJxR